QUALITY OF LIFE

生活质量

基本信息

  • 批准号:
    6563775
  • 负责人:
  • 金额:
    $ 7.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-01-11 至 2002-12-31
  • 项目状态:
    已结题

项目摘要

Our primary goal is to assess only relevant endpoints that have tangible outcomes for cancer patients and clinical practice. Over the previous grant period, QOL research has been organized into a programmatic approach following three themes: 1) assessing QOL endpoints efficiently within treatment trials; 2) designing trials targeted specifically to QOL endpoints; and 3) developing new QOL methodology. Cancer treatment delivery can be improved through direct intervention to impact QOL endpoints, improved QOL assessment methods, or interventions to ameliorate concomitant side effects. A barrier to the development of these research efforts has been the lack of dedicated resources. Preliminary Work: A guiding principle of our preliminary work can be summarized as "less is more". We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- tem tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a prior clinically significant effect sizes. Preliminary Work: A guiding principle of our preliminary work can be summarized as "less is more." We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- item tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a priori clinically significant effect sizes. Clinical trials work includes pilot studies that target QOL endpoints (such social support) which impact directly on the ability to receive and tolerate cancer treatments and special populations (e.g., the elderly). Methodological advances include new tools, approaches, and analytical methods for combining QOL data with the traditional treatment endpoints of survival and response. This work also impacts the design of and accrual to cancer treatment trials. Future Directions: We have identified major issues for QOL research which will be addressed across all disease committees. We will define clinical significance for QOL endpoints by hosting an international meeting with the purpose of drafting a consensus document. Other research targets the use of individual questions as clinical intervention triggers and the use of proxy respondents to address the issue of missing data. We will construct an assessment package to identify frail elderly cancer patients so that modified treatments can be developed and linkage programs established within the community oncology practices to address deficits in individual patient social support. We will also explore the use of complementary therapies for pain management, including music and massage. Summary: The unique community practice-based structure of NCCTG has fostered the development of efficient, programmatic, and pragmatic, and pragmatic QOL research. We are at a critical juncture whereupon the present activity can be grown into a fully funded and functional program.
我们的主要目标是仅评估对癌症患者和临床实践具有切实结果的相关终点。在之前的资助期间,生活质量研究已被组织成以下三个主题的程序化方法:1)在治疗试验中有效评估生活质量终点;2)设计针对生活质量终点的试验;3)发展新的生活质量方法。可以通过直接干预影响生活质量终点、改进生活质量评估方法或干预改善伴随副作用来改善癌症治疗交付。发展这些研究工作的一个障碍是缺乏专门的资源。前期工作:前期工作的指导原则是“少即是多”。我们证明,单一项目的全球生活质量仪器比针对相同结构的多项目工具对变化的敏感性更高。我们使用了最小限度的足够的个体生活质量项目集和先前的临床显著效应量。前期工作:前期工作的指导原则是“少即是多”。我们证明了一个单一项目的全球生活质量仪器比一个针对相同结构的多项目工具对变化的敏感度更高。我们使用了最少足够的个体生活质量项目集和先验的临床显著效应量。临床试验工作包括针对生活质量终点(如社会支持)的试点研究,这些终点直接影响接受和耐受癌症治疗的能力以及特殊人群(如老年人)。方法学的进步包括将生活质量数据与传统的生存和反应治疗终点相结合的新工具、方法和分析方法。这项工作也影响了癌症治疗试验的设计和累积。未来方向:我们已经确定了生活质量研究的主要问题,这些问题将在所有疾病委员会中得到解决。我们将通过主持一次国际会议,起草一份共识文件,确定生活质量终点的临床意义。其他研究的目标是使用个人问题作为临床干预触发器,并使用代理受访者来解决缺失数据的问题。我们将构建一个评估包来识别体弱多病的老年癌症患者,以便改进治疗方法,并在社区肿瘤实践中建立联系项目,以解决个体患者社会支持的缺陷。我们还将探索使用辅助疗法来管理疼痛,包括音乐和按摩。摘要:NCCTG独特的基于社区实践的结构促进了高效、程序化和务实的QOL研究的发展。我们正处于一个关键的时刻,在这个时刻,目前的活动可以发展成为一个资金充足、功能齐全的项目。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeff A. Sloan其他文献

The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression
  • DOI:
    10.1186/s12882-017-0578-6
  • 发表时间:
    2017-05-25
  • 期刊:
  • 影响因子:
    2.400
  • 作者:
    Myrte K. Neijenhuis;Wietske Kievit;Ronald D. Perrone;Jeff A. Sloan;Patricia Erwin;Mohammad Hassan Murad;Tom J. G. Gevers;Marie C. Hogan;Joost P. H. Drenth
  • 通讯作者:
    Joost P. H. Drenth
729. Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients
  • DOI:
    10.1016/j.ymthe.2006.08.809
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Evanthia Galanis;Lynn C. Hartmann;William A. Cliby;Paula Zollman;Prema P. Peethambaram;Harry J. Long;Judith S. Kaur;Jeff A. Sloan;Gregory A. Poland;Kah-Whye Peng;Stephen J. Russell
  • 通讯作者:
    Stephen J. Russell
The 2009 National Consensus Project for Quality Palliative Care (NCP) Guidelines (400)
  • DOI:
    10.1016/j.jpainsymman.2009.02.075
  • 发表时间:
    2009-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea M. Barsevick;Charles S. Cleeland;Donald C. Manning;Ann M. O'Mara;Bryce B. Reeve;Jane A. Scott;Jeff A. Sloan
  • 通讯作者:
    Jeff A. Sloan
Management of Pruritus in Hospice and Palliative Care (405)
  • DOI:
    10.1016/j.jpainsymman.2009.02.080
  • 发表时间:
    2009-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea M. Barsevick;Charles S. Cleeland;Donald C. Manning;Ann M. O'Mara;Bryce B. Reeve;Jane A. Scott;Jeff A. Sloan
  • 通讯作者:
    Jeff A. Sloan
Pain in Heart Failure: Is It Different? (411-C)
  • DOI:
    10.1016/j.jpainsymman.2009.02.092
  • 发表时间:
    2009-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea M. Barsevick;Charles S. Cleeland;Donald C. Manning;Ann M. O'Mara;Bryce B. Reeve;Jane A. Scott;Jeff A. Sloan
  • 通讯作者:
    Jeff A. Sloan

Jeff A. Sloan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeff A. Sloan', 18)}}的其他基金

Assessing PROMIS and other simple patient-reported measures for cancer research
评估 PROMIS 和其他简单的患者报告的癌症研究措施
  • 批准号:
    8185607
  • 财政年份:
    2011
  • 资助金额:
    $ 7.89万
  • 项目类别:
Assessing PROMIS and other simple patient-reported measures for cancer research
评估 PROMIS 和其他简单的患者报告的癌症研究措施
  • 批准号:
    8879059
  • 财政年份:
    2011
  • 资助金额:
    $ 7.89万
  • 项目类别:
Assessing PROMIS and other simple patient-reported measures for cancer research
评估 PROMIS 和其他简单的患者报告的癌症研究措施
  • 批准号:
    8680178
  • 财政年份:
    2011
  • 资助金额:
    $ 7.89万
  • 项目类别:
Assessing PROMIS and other simple patient-reported measures for cancer research
评估 PROMIS 和其他简单的患者报告的癌症研究措施
  • 批准号:
    9087161
  • 财政年份:
    2011
  • 资助金额:
    $ 7.89万
  • 项目类别:
Assessing PROMIS and other simple patient-reported measures for cancer research
评估 PROMIS 和其他简单的患者报告的癌症研究措施
  • 批准号:
    8307765
  • 财政年份:
    2011
  • 资助金额:
    $ 7.89万
  • 项目类别:
QUALITY OF LIFE
生活质量
  • 批准号:
    6665607
  • 财政年份:
    2002
  • 资助金额:
    $ 7.89万
  • 项目类别:
Oncology QOL Clinical Significance Consensus Meeting
肿瘤学 QOL 临床意义共识会议
  • 批准号:
    6545065
  • 财政年份:
    2002
  • 资助金额:
    $ 7.89万
  • 项目类别:
ONCOLOGY QOL CLINICAL SIGNIFICANCE CONSENSUS MEETING
肿瘤学 QOL 临床意义共识会议
  • 批准号:
    6228792
  • 财政年份:
    2000
  • 资助金额:
    $ 7.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了